11.23

2.56% 0.28

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $11.23, with a volume of 540.17K. It is up +2.56% in the last 24 hours and down -2.60% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Previous Close:

$10.95

Open:

$10.93

24h Volume:

540.17K

Relative Volume:

0.85

Market Cap:

$768.33M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-3.7811

EPS:

-2.97

Net Cash Flow:

$-176.27M

1W Performance:

-3.93%

1M Performance:

-2.60%

6M Performance:

+89.06%

1Y Performance:

+10.31%

1-Day Range:

$10.75

$11.29

1-Week Range:

$10.57

$11.73

52-Week Range:

$4.92

$12.97

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

331

Twitter

@Replimune

Next Earnings Date

2024-11-05

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL	11.23	768.33M	0	-209.96M	-176.27M	-2.97
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

12:53 PM

Replimune's chief commercial officer sells $56,131 in stock By Investing.com - Investing.com Nigeria

12:53 PM

Nov 20, 2024

Replimune group's chief medical officer sells shares worth $78,111 By Investing.com - Investing.com Canada

Nov 20, 2024

Replimune's chief commercial officer sells $56,131 in stock - Investing.com

Nov 20, 2024

REPL (Replimune Group) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP - MarketBeat

Nov 20, 2024

Nov 17, 2024

Significant Stake Increase by Baker Bros. Advisors in Replimune Group Inc - GuruFocus.com

Nov 15, 2024

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $16.80 - Defense World

Nov 15, 2024

Nov 14, 2024

When (REPL) Moves Investors should Listen - Stock Traders Daily

Nov 14, 2024

Nov 13, 2024

Replimune Group’s Q3 2024 Financial Highlights - TipRanks

Nov 13, 2024